Anthony leads the workstream on physiological assessment within the Improved Patient Outcomes theme. A Palliative Medicine physician in Cardiff, Anthony is also the Clinical Director of the Marie Curie Palliative Care Research Centre at Cardiff University. His particular areas of research interest are palliative rehabilitation, pragmatic study design and implementation, and patient experience methodologies. He is a member of the Palliative and Supportive Care subgroup of the NCRI Brain CSG and the End of Life Board for Wales. He is also research lead for Palliative Care at Cardiff and Vale University Health Board where his clinical practice is based.
Kevin is the director of clinical PET research at the Wales Research and Diagnostic Positron Emission Tomography Centre (PETIC), at the University Hospital of Wales, in Cardiff.
Kevin is a clinical radiologist and nuclear medicine physician specialising in PET and diagnostic nuclear medicine. He has wide ranging imaging research interests with publications defining the role of PET/CT in oesophageal carcinoma, gastric carcinoma and sarcomas as well as optimising PET reconstruction algorithms.
He is currently Chairman of ARSAC (Administration of Radioactive Substances Advisory Committee), an expert committee required to licence any diagnostic, research or therapy administration of a radioactive substance to a human in the UK.
Sue has been involved with cancer from a very early age. The female side of her family has been decimated with ovarian cancer. She has had cancer herself and been a full time carer.
Her working life started as a lab technician with the Medical Research Council. She then joined the British Museum of Natural History looking after the fossil fish and dinosaurs.
The bulk of her working life was spent with the Ministry of Agriculture Fisheries and Food. Her main interests being in public health insects, namely Pharaohs Ants and cockroaches, and their medical significance. She has published a number of papers in the UK and the USA. She took early retirement to look after her late husband, formed her own auditing consultancy and joined the local Community Health Council which gave her considerable insight into NHS services and patient needs. She was a member of their Executive and chaired two of their committees.
She joined the Wales Cancer Research Centre as a research partner five years ago and has been involved in developing a number of trials here in Wales and in Oxford and London. She has developed a considerable interest in radiotherapy of all types and joined the Royal Society of Radiologists as a lay representative. She is chair of the Wales Cancer Bank Lay Liaison and Ethics Group.
She has helped establish a lay faculty training course for new researchers dealing with plain English summaries, use of scientific jargon, early protocols, funding applications etc. She has held a number of these courses and presented at an immunity conference.
Dr Clarkson is Reader in Cancer Studies at Cardiff University and was Translational Theme lead for WCRC until 2020. In his new role as Science Director of the Wales Cancer Bank, which received independent infrastructure funding from HCRW in 2020, Dr Clarkson’s involvement on the WCRC Executive Committee will provide an important line of communication between the activities of WCRC and the Wales Cancer Bank, ensuring unfettered access of cancer samples to the WCRC research community. The shared vision of WCB and WCRC for an integrated approach to cancer research in Wales, involving the collation and integration of clinical, genomic and imaging data with patient’s biological samples, lies at the heart of their joint aspirations for improving the health prospects of cancer patients in Wales.
Richard Clarkson is Senior Lecturer of cancer research in the School of Biosciences and is academic mentor for the research fellows in the European Cancer Stem Cell Research Institute.
Richard received his PhD from the Faculty of Medicine, University of Manchester and carried out research at the Universities of Queensland, Edinburgh and Cambridge before moving to Cardiff in 2005. Having worked for more than 10 years on the biology of the mammary gland and the regulation of epithelial cell apoptosis, Richard’s research group now focuses on applying this knowledge to identify novel therapeutic strategies to eliminate or modify the cancer cells responsible for the spread of tumours around the body – often referred to as the cancer stem cells.
Current responsibilities and positions:
Deputy Director of the European Cancer Stem Cell Research Institute https://www.cardiff.ac.uk/cancer-stem-cell
Science Director of Wales Cancer Bank (WCB): http://www.walescancerbank.com
Theme Lead for Wales Cancer Research Centre (WCRC): https://www.walescancerpartnership.com/wcrc/
Vice-chair of WCRC Multi-disciplinary Research Group for Prostate Cancer
Member of Scientific Advisory Board for Breast Cancer Now: http://breastcancernow.org
Research Integrity Lead, Cardiff University College of Biological Lifesciences
Academic Team Lead, School of Biosciences, Cardiff University
Kate develops processes to support the members of the public who contribute and form a key role in the Centre’s work. She facilitates the governance the Centre and delivers the coordination of the WCRC including reporting on the Centre’s progress and organising conferences in collaboration with key stakeholders.
Steve is the Industry and Innovation lead for the Wales Cancer Research Centre and an academic research scientist. He is Professor of Molecular and Cell Biology heading up the vibrant Reproductive Biology and Gynaecological Oncology group in Swansea University’s Medical School, where he is also Head of Enterprise and Innovation.
His research interests are in gynaecological pathologies including cancer and infertility, working on transcription and epigenetic disease processes, and the development of advanced therapeutics; Antibody Drug Conjugates (pre-clinical development), exosomes, and nanoparticle deliver systems. He was a founding Director of the Centre for NanoHealth at Swansea University, and is now Strategic Director of the Celtic Advanced Life Science Innovation Network (CALIN).
Steve holds various roles including programme board member on two of Wales’ national precision medicine initiatives: Advanced Therapies Wales and Genome Partnerships Wales, where he chairs the Research and Innovation workstream. He is a Fellow of the Royal Society of Biology (FRSB), and a Trustee of the British Society of Nanomedicine. He is a Senior Affiliate Member of The Methodist Hospital Research Institute, Houston Texas, Distinguished Professor at Xi'an Jiaotong University, Suzhou Academy, China, and honorary consultant in the Swansea Bay University Health Board.
Dr Mark Davies is a Consultant Medical Oncologist, specialising in breast cancer at the South West Wales Cancer Centre (SWWCC) in Swansea and Honorary Associate Professor at Swansea University Medical School.
Mark is dually accredited in medical oncology and clinical genetics. In his role as a clinical geneticist, he has focused on the care of inherited tumour predisposition syndromes and has established clinics to co-ordinate the care needed by patients with tuberous sclerosis, a rare tumour predisposition syndrome, and for children with an inherited risk of cancer.
His research interests focus on novel means to target mTOR signalling in cancer and on integrating genomics into mainstream oncology. He is a member of the National Cancer Research Institute Children’s Cancer Clinical Research Group and the All Wales Genetic Oncology Group. He is currently the local lead investigator for several breast cancer trials and is systemic therapy research lead at SWWCC.
Joshua Ford is a professional has a science degree from the Plymouth University and has diverse experience in the scientific and private sectors. He has been the Wales Cancer Research Centre since early 2019.
As project support, his roles include coordinating meetings and internal and external events, assisting reports of publications, research awards and funding granted to the university to inform key stakeholders of the Centre’s progress.